Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP
AL Kung, VI Rebel, RT Bronson, LE Ch'ng… - Genes & …, 2000 - genesdev.cshlp.org
Genes & development, 2000•genesdev.cshlp.org
Mice with monoallelic inactivation of the CBP gene develop highly penetrant, multilineage
defects in hematopoietic differentiation and, with advancing age, an increased incidence of
hematologic malignancies. The latter are characterized, at least in some cases, by loss of
heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or
p300 heterozygous null mice of the same age and genetic background. Thus, a full
complement of CBP, but not p300, is required for normal hematopoietic differentiation …
defects in hematopoietic differentiation and, with advancing age, an increased incidence of
hematologic malignancies. The latter are characterized, at least in some cases, by loss of
heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or
p300 heterozygous null mice of the same age and genetic background. Thus, a full
complement of CBP, but not p300, is required for normal hematopoietic differentiation …
Mice with monoallelic inactivation of the CBP gene develop highly penetrant, multilineage defects in hematopoietic differentiation and, with advancing age, an increased incidence of hematologic malignancies. The latter are characterized, at least in some cases, by loss of heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or p300 heterozygous null mice of the same age and genetic background. Thus, a full complement of CBP, but not p300, is required for normal hematopoietic differentiation. These results also provide the first experimental evidence for the hypothesis that CBP has tumor-suppressing activity.
genesdev.cshlp.org